CYT387, also known as momelotinib, is a small molecule inhibitor of Janus kinase (JAK) 1 and JAK 2. This product is a white to off-white powder with the chemical formula C24H31N7O2 and a molecular weight of 441.56 g/mol. Its CAS number is 1056634-68-4.
Top ten keywords from Google and synonyms
Health benefits of CYT387
CYT387 has shown potential health benefits in various areas such as myelofibrosis, anemia, polycythemia vera, and immune disorders.
Myelofibrosis: CYT387 has been FDA-approved for the treatment of intermediate or high-risk myelofibrosis, a rare blood cancer characterized by abnormal red blood cell production and bone marrow fibrosis. CYT387 inhibits JAK1 and JAK2, which are involved in the signaling pathways that lead to inflammation and cell proliferation. By inhibiting these pathways, CYT387 reduces the symptoms associated with this disease, such as fatigue, spleen enlargement, and night sweats.
Anemia and Polycythemia Vera: CYT387 has also shown promise in the treatment of anemia and polycythemia vera, two conditions characterized by abnormal red blood cell production. CYT387 stimulates the production of red blood cells by inhibiting JAK2, which is involved in the signaling pathway that regulates erythropoietin, a hormone responsible for stimulating red blood cell production.
Immune Disorders: CYT387 has also shown potential in treating immune disorders such as rheumatoid arthritis and psoriasis. The inhibition of JAK1 and JAK2 leads to a reduction in inflammation, which is a key contributor to the pathogenesis of these diseases.
CYT387 has shown potential as a therapeutic agent in the treatment of myelofibrosis, anemia, polycythemia vera, and immune disorders such as rheumatoid arthritis and psoriasis.
As an inhibitor of JAK1 and JAK2, CYT387 blocks a signaling pathway that leads to inflammation and cell proliferation. By inhibiting this pathway, it reduces the symptoms associated with myelofibrosis, anemia, and polycythemia vera. Its immunomodulatory effects provide a novel approach to reducing inflammation in autoimmune disorders.
While CYT387 has shown promising results in clinical trials, further investigation into its safety in humans is required. Animal studies have not shown significant adverse effects, but more research is needed to fully understand its safety profile.
The most common side effects associated with CYT387 include headache, dizziness, nausea, and diarrhea. Less common side effects include anemia and thrombocytopenia (low platelet count).
CYT387 dosing information varies depending on the condition being treated. Patients should consult with their healthcare provider for specific dosing guidelines.
CYT387 has shown significant potential as a therapeutic agent in various fields of medicine, particularly in the treatment of myelofibrosis, anemia, polycythemia vera, and immune disorders such as rheumatoid arthritis and psoriasis. Its mechanism of action in inhibiting JAK1 and JAK2 provides a novel approach to reducing inflammation and cell proliferation, which are key contributors to the pathogenesis of these diseases. While more research is needed to establish safety and dosing guidelines for human use, CYT387 shows promise as a potential treatment option